💊 MERCK & CO. (NYSE: MRK)

STOCKINSIGHT™ STOCK INITIATION REPORT

━━━━━━━━━━━━━━━━━━

📋 MANAGEMENT SUMMARY

━━━━━━━━━━━━━━━━━━

• We maintain a BUY / OVERWEIGHT rating on Merck.

• At $131.07, MRK has recovered strongly and is now trading near its 52-week high, supported by renewed investor confidence in its pipeline and new growth opportunities.

• The company remains one of the highest-quality pharmaceutical companies globally, with Keytruda, vaccines, animal health, and a growing oncology pipeline supporting long-term earnings power.

• The biggest strategic challenge remains the upcoming Keytruda patent expiration risk starting in 2028, making pipeline execution and new product launches critical.

• Recent positive developments, including FDA approvals and pipeline progress, have improved sentiment around Merck’s ability to replace future lost revenue.

• Key catalyst: Q2 earnings, new product launches, and further pipeline updates.

🟢 RATING: BUY / OVERWEIGHT

🎯 12-MONTH PRICE TARGET: $150

💵 CURRENT PRICE: $131.07

📈 IMPLIED UPSIDE: +14.4%

💰 DIVIDEND YIELD: ~2.6%

🗓️ NEXT EARNINGS DATE: August 4, 2026 (Estimated)

━━━━━━━━━━━━━━━━━━

⚡ QUICK SNAPSHOT

━━━━━━━━━━━━━━━━━━

🏢 Market Cap: ~$330B

💊 Major Products:

• Keytruda (Oncology)

• Gardasil (HPV Vaccine)

• Animal Health

• Pneumococcal Vaccines

• Cardiovascular Pipeline

📦 Investment Theme:

Defensive Healthcare + Oncology Growth + Pipeline Renewal

━━━━━━━━━━━━━━━━━━

📈 STOCK PERFORMANCE

━━━━━━━━━━━━━━━━━━

💵 Current Price: $131.07

🟢 Near 52-week highs

🟢 Strong recent momentum

🟢 Outperforming several large pharma peers

📊 Relative Performance

✅ Defensive healthcare exposure

✅ Strong cash generation

✅ Attractive dividend profile

⚠️ Valuation now reflects improved expectations

🔥 Momentum Trend:

➡️ Positive trend with improving investor confidence.

━━━━━━━━━━━━━━━━━━

📰 WHAT CHANGED RECENTLY?

━━━━━━━━━━━━━━━━━━

Merck sentiment improved after several important developments:

🟢 FDA approval expansion for Keytruda combinations.

🟢 Progress toward new growth drivers beyond Keytruda.

🟢 Positive reaction to Lipfendra, Merck’s oral cholesterol-lowering therapy approval, which could become a meaningful future commercial opportunity.

However:

⚠️ Investors remain focused on replacing Keytruda revenue before patent expiration.

━━━━━━━━━━━━━━━━━━

📰 RECENT NEWS FLOW (LAST 2 WEEKS)

━━━━━━━━━━━━━━━━━━

🟢 Positive Developments

✅ Merck received regulatory approval for Lipfendra, the first oral PCSK9 inhibitor, creating a potential new cardiovascular growth opportunity.

✅ Keytruda-related approvals and pipeline progress continue strengthening Merck’s long-term oncology franchise.

🔴 Negative Developments

⚠️ Investors remain concerned about Keytruda’s patent cliff beginning in 2028 and the need for replacement revenue streams.

⚠️ After the recent rally, expectations have increased and valuation support is less compelling than earlier in the year.

━━━━━━━━━━━━━━━━━━

🚀 INVESTMENT THESIS

━━━━━━━━━━━━━━━━━━

Merck is transitioning from:

➡️ Keytruda-dependent pharmaceutical giant

into

➡️ Diversified healthcare innovation company.

Key positives:

✅ Global oncology leadership

✅ Strong pharmaceutical pipeline

✅ Vaccine franchise

✅ Dividend growth

✅ Significant R&D capabilities

━━━━━━━━━━━━━━━━━━

🔥 3 CORE BULLISH PILLARS

━━━━━━━━━━━━━━━━━━

1️⃣ Oncology Leadership

✔ Keytruda remains one of the world’s most successful cancer drugs.

✔ Expanding indications continue extending commercial value.

Our View:

➡️ Oncology remains Merck’s strongest competitive advantage.

━━━━━━━━━━━━━━━━━━

2️⃣ Pipeline Replacement

✔ New oncology therapies

✔ Cardiovascular opportunities

✔ Strategic acquisitions

Our View:

➡️ Pipeline success will determine Merck’s next decade.

━━━━━━━━━━━━━━━━━━

3️⃣ Defensive Healthcare Position

✔ Stable demand

✔ Strong cash flow

✔ Dividend support

Our View:

➡️ MRK provides portfolio stability during volatile markets.

━━━━━━━━━━━━━━━━━━

📊 FINANCIAL SNAPSHOT

━━━━━━━━━━━━━━━━━━

💰 FY26E (Current Fiscal Year)

Revenue: ~$70B+

EPS: ~$9.00

Free Cash Flow: Strong

Dividend: Growing

💰 FY27E

Revenue Growth: Moderate

EPS Growth: Supported by pipeline launches

💰 FY28E

Keytruda transition becomes the major investor focus.

━━━━━━━━━━━━━━━━━━

📈 OUR VIEW VS WALL STREET

━━━━━━━━━━━━━━━━━━

Pipeline

Consensus: Improving

Our View: Critical upside driver

Keytruda Risk

Consensus: Concern

Our View: Manageable if pipeline executes

Valuation

Consensus: Fair

Our View: Still attractive for quality

━━━━━━━━━━━━━━━━━━

📅 POSITIVE CATALYSTS

━━━━━━━━━━━━━━━━━━

🟢 Strong Q2 Earnings

🟢 Keytruda Expansion

🟢 Lipfendra Commercial Success

🟢 Pipeline Breakthroughs

🟢 Dividend Growth

🟢 Oncology Acquisitions

━━━━━━━━━━━━━━━━━━

⚠️ NEGATIVE CATALYSTS

━━━━━━━━━━━━━━━━━━

🔴 Keytruda Patent Cliff

🔴 Drug Pricing Pressure

🔴 Clinical Trial Failures

🔴 Regulatory Delays

🔴 Healthcare Policy Changes

━━━━━━━━━━━━━━━━━━

📊 SENTIMENT & POSITIONING

━━━━━━━━━━━━━━━━━━

✅ Institutional ownership remains strong.

✅ Defensive healthcare demand remains attractive.

✅ Investor confidence improving.

⚠️ Future growth depends heavily on pipeline execution.

Market sentiment:

➡️ Constructive with long-term concerns already known.

━━━━━━━━━━━━━━━━━━

🐂 BULL VS 🐻 BEAR CASE

━━━━━━━━━━━━━━━━━━

🐂 Bull Case: $165

✔ Pipeline delivers

✔ Lipfendra becomes major product

✔ Oncology growth continues

✔ Multiple expansion

🐻 Bear Case: $110

⚠️ Keytruda decline faster than expected

⚠️ Pipeline disappoints

⚠️ Pharma valuation pressure

🎯 Base Case: $150

━━━━━━━━━━━━━━━━━━

🎯 SUPPORT & RESISTANCE LEVELS

━━━━━━━━━━━━━━━━━━

🟢 Key Support Levels

S1: $125

S2: $118

S3: $110

🔴 Key Resistance Levels

R1: $132

R2: $140

R3: $150

📌 Trading Interpretation

➡️ Holding above $125 keeps the bullish setup intact.

➡️ A breakout above $132-$135 could open the path toward $150.

➡️ Earnings and pipeline updates remain the biggest drivers.

━━━━━━━━━━━━━━━━━━

📉 TECHNICAL SETUP

━━━━━━━━━━━━━━━━━━

📈 Long-Term Trend: Bullish

📊 Relative Strength: Strong

🔥 Momentum: Positive

⚠️ Valuation: Fair

💰 Dividend Support: Strong

━━━━━━━━━━━━━━━━━━

✅ FINAL TAKE

━━━━━━━━━━━━━━━━━━

Merck has transformed from a pure Keytruda story into a broader healthcare growth and income opportunity.

At $131.07, the stock is no longer deeply undervalued, but the combination of:

✅ Strong oncology franchise
✅ New product opportunities
✅ Defensive earnings
✅ Dividend income

creates an attractive long-term profile.

The biggest question remains whether Merck can successfully replace Keytruda revenue before the patent cliff arrives. Current pipeline progress suggests the company is moving in the right direction.

🟢 RATING: BUY / OVERWEIGHT

🎯 PRICE TARGET: $150

📈 UPSIDE POTENTIAL: +14.4%

Risk Level: 🔥🔥🔥 Medium

Reward Potential: 🔥🔥🔥🔥 Medium-High

Conviction: ⭐⭐⭐⭐☆ (8/10)

#StockInsight #MRK #Merck #PharmaStocks #HealthcareStocks #DividendStocks #Biotech #ValueInvesting #StockAnalysis #StockInsight